Hayashi, Keitaro published the artcileAntitumor effect of dimethyl itaconate on thymic carcinoma by targeting LDHA-mTOR axis, Safety of Dimethyl itaconate, the publication is Life Sciences (2021), 119847, database is CAplus and MEDLINE.
Thymic carcinoma is a rare type of cancer without an established standard pharmaceutical treatment. This study investigated the antitumor effect of di-Me itaconate (DI), a cell-permeable derivative of itaconate, on human thymic carcinoma cell line. Human thymic carcinoma cell line Ty82 was used to evaluate the effect of DI on cell viability. Western blotting and immunohistochem. were performed to determine the mol. mechanism of antitumor effects of DI on Ty82. DI suppressed cell growth and promoted apoptosis of Ty82. The suppressive effect of DI on Ty82 was mediated by the downregulation of lactate dehydrogenase A (LDHA), and the subsequent decrease in the activity of mechanistic target of rapamycin (mTOR). DI exhibited synergistic antitumor effects with a specific inhibitor of large neutral amino acid transporter 1 (LAT1), an amino acid transporter currently being investigated as a novel target for cancer therapy. Our findings demonstrate that DI is a novel potential strategy for thymic carcinoma treatment.
Life Sciences published new progress about 617-52-7. 617-52-7 belongs to esters-buliding-blocks, auxiliary class Alkenyl,Aliphatic hydrocarbon chain,Ester, name is Dimethyl itaconate, and the molecular formula is C7H10O4, Safety of Dimethyl itaconate.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics